US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
According to Jinse Finance, on Thursday, SuperX AI Technology (SUPX.US) saw its share price decline, dropping more than 2.5% at one point to hit an intraday low of $6.46. In related news, the company announced the launch of an upgraded version of its Artificial Intelligence Innovation Center (AIIC 2.0), featuring a new "Model as a Service" functionality. This allows enterprises to directly access deployed AI models without having to build and maintain their own model operating environments, thereby lowering the barriers for businesses to adopt artificial intelligence technology.
It is understood that the AIIC was jointly developed by SuperX and data center operator STTGDC. It was announced on April 15, 2026, at the STT Singapore 5 data center facility located in the Dadeng region of Singapore.
The newly added "Model as a Service" feature in AIIC 2.0 enables customers to use already deployed AI models directly through an Application Programming Interface (API). This means companies do not have to allocate computing resources or take responsibility for daily model maintenance, allowing them to integrate AI capabilities into their business systems with ease.
SuperX stated that the upgraded AIIC 2.0 will offer services to enterprises and institutions in Singapore and other Southeast Asian regions, supporting customers in testing and validating various AI applications and helping them gradually expand pilot projects to broader business scenarios.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
